A study on the safety profile and clinical outcomes in patients using tulobuterol transdermal patch as an add on therapy in stable chronic obstructive pulmonary disease

---

Original Article

Author Details : Radhika R*, Beena Thomas, Ahmed Rafad, Jerin James, Mekha Monsi Chenthiyethu, Ruben Thomas Lal

Volume : 7, Issue : 1, Year : 2022

Article Page : 16-20

https://doi.org/10.18231/j.ijirm.2022.005

Suggest article by email

Get Permission

---

Abstract

Background: Tulobuterol Transdermal Drug Delivery (TTD) may be beneficial in COPD management. We aimed to study the effect of adding TTD to Triple Inhalation therapy (TI).
Materials and Methods: Participants on TTD and TI (TTD-TI cohort) and, TI only (TI cohort) were identified at the out-patient pharmacy counter. There was no loss to follow-up from 35 participants each enrolled in the cohorts. They were assessed with Modified British Medical Research Council questionnaire (modified Medical Research Council), COPD Control Questionnaire (CCQ) and COPD Assessment Test (CAT). The latter two were repeated at the end of six months. The change in score were compared with Mann-Whitney-U test.
Results: Mean age of participants in years was 63.4 and 65.7; 31% and 20% were females and rest were males in TTD-TI and TI cohorts respectively. All of them had modified Medical Research Council grade 2 or above. CCQ and CAT scores were comparable at baseline. Change in both CCQ and CAT scores were statistically significant between the cohorts (p<0> Conclusions: There would be a subjective improvement with addition of tulobuterol transdermal patch on to triple inhalation therapy for older persons with COPD.
 

Keywords: Tulobuterol Transdermal Patch, Long Acting Beta-2 Agonists, Chronic Obstructive Pulmonary Disease, Triple Inhalation Therapy, COPD Assessment Test

How to cite : Radhika R, Thomas B, Rafad A, James J, Chenthiyethu M M, Lal R T, A study on the safety profile and clinical outcomes in patients using tulobuterol transdermal patch as an add on therapy in stable chronic obstructive pulmonary disease. IP Indian J Immunol Respir Med 2022;7(1):16-20

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.